Antidiabetic oxazolidinediones and thiazolidinediones as agonists or partial agonists of PPAR gamma

摘要

Disclosed is a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: A is O or S; X is a bond or CH2; R1 is selected from the group consisting of H and C1-C3 alkyl, wherein C1-C3 alkyl is optionally substituted with 1-3 F; Each R2 is independently selected from the group consisting of F, Cl, CH3, CF3, -OCH3, and -OCF3; Each R4 is independently selected from the group consisting of halogen, C1-C3 alkyl, -OC1-C3 alkyl, -OC(=O)C1-C3 alkyl, and -S(O)qC1-C3 alkyl, wherein C1-C3 alkyl, -OC1-C3 alkyl, -OC(=O)C1-C3 alkyl, and -S(O)qC1-C3 alkyl are optionally substituted with 1-3 F; Each R5 is independently selected from the group consisting of F, Cl, CH3, -OCH3, CF3, and -OCF3; R6 is selected from the group consisting of C2-C5 alkyl, -CH2Cyclopropyl, and -C(=O)C1-C3 alkyl, wherein said R6 substituent is optionally substituted with 1-3 F; m is 0 or 1; n is an integer from 1-3; P is an integer from 0-2; and q is an integer from 0-2. Also disclosed is a pharmaceutical composition comprising of the said compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and additionally, the use of the said compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of Type 2 diabetes is also disclosed.